H. Lundbeck A/S
HLUN-A
Kedudukan dalam Saham
#2971
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Harga Saham
$7.44
Modal Pasaran
$6.22B
Perubahan (1 hari)
0.43%
Perubahan (1 tahun)
35.28%
Negara
DK
Perdagangan H. Lundbeck A/S (HLUN-A)
Kategori
Healthcare
Nisbah P/B bagi H. Lundbeck A/S (HLUN-A)
Nisbah P/B pada October 2026 TTM: 1.75
Menurut laporan kewangan dan harga saham terkini H. Lundbeck A/S, nisbah P/B semasa (TTM) ialah 1.75. Pada akhir 2024, nisbah P/B syarikat ialah 1.64.
Sejarah nisbah P/B untuk H. Lundbeck A/S dari 2004 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun | Nisbah P/B | Ubah |
|---|---|---|
| 2026 (TTM) | 1.75 | 1.69% |
| 2025 | 1.72 | 4.98% |
| 2024 | 1.64 | 11.09% |
| 2023 | 1.47 | 18.46% |
| 2022 | 1.24 | -11.90% |
| 2021 | 1.41 | 271.33% |
| 2020 | 0.38 | -1.12% |
| 2019 | 0.38 | -15.07% |
| 2018 | 0.45 | -14.02% |
| 2017 | 0.53 | -20.28% |
| 2016 | 0.66 | -9.04% |
| 2015 | 0.73 | 54.11% |
| 2014 | 0.47 | -0.25% |
| 2013 | 0.47 | -2.11% |
| 2012 | 0.48 | -3.17% |
| 2011 | 0.50 | -12.96% |
| 2010 | 0.57 | -20.84% |
| 2009 | 0.72 | -14.99% |
| 2008 | 0.85 | -8.14% |
| 2007 | 0.93 | -8.58% |
| 2006 | 1.01 | 4.11% |
| 2005 | 0.97 | 2.35% |
| 2004 | 0.95 | 0.00% |
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/B | Perbezaan Nisbah P/B | Negara |
|---|---|---|---|
| 3.8424 | 119.68% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 17.3539 | 892.16% |
US
|
